Cibus (NASDAQ:CBUS) Trading Up 5.1% – Should You Buy?

Cibus, Inc. (NASDAQ:CBUS) rose 5.1% on Monday . The stock traded as high as $1.43 and last traded at $1.43. 251,486 shares traded hands during mid-day trading, a decline of 7% from the average session volume of 269,288 shares. The stock had previously closed at $1.36.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CBUS shares. Weiss Ratings upgraded Cibus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. Jefferies Financial Group upped their price target on Cibus from $1.90 to $3.00 and gave the stock a “hold” rating in a report on Wednesday, March 25th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Cibus has an average rating of “Hold” and an average price target of $9.00.

Cibus Stock Up 5.1%

The company has a market capitalization of $109.15 million, a price-to-earnings ratio of -0.73 and a beta of 1.64. The firm has a 50 day moving average price of $1.39 and a two-hundred day moving average price of $1.96.

Cibus (NASDAQ:CBUS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.06). The business had revenue of $1.68 million during the quarter, compared to analyst estimates of $1.61 million. Cibus had a negative return on equity of 200.87% and a negative net margin of 2,366.33%. Analysts predict that Cibus, Inc. will post -1.18 earnings per share for the current year.

Hedge Funds Weigh In On Cibus

Several institutional investors and hedge funds have recently made changes to their positions in the business. Weiss Asset Management LP acquired a new stake in shares of Cibus during the first quarter worth approximately $1,758,000. Prescott Group Capital Management L.L.C. bought a new stake in shares of Cibus in the fourth quarter worth $345,000. Jane Street Group LLC acquired a new stake in Cibus in the second quarter valued at $207,000. Certior Financial Group LLC raised its holdings in Cibus by 46.7% in the fourth quarter. Certior Financial Group LLC now owns 271,164 shares of the company’s stock valued at $472,000 after acquiring an additional 86,378 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in Cibus during the 4th quarter valued at $145,000. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.